Eisai Report Five-Year Leqembi Data Showing Sustained Alzheimer's Benefit
(RTTNews) - BioArctic AB's partner Eisai Co., Ltd. (4523.T) presented long-term data from the Phase 3 Clarity AD trial showing that continuous treatment with LEQEMBI (lecanemab-irmb) provided sustained benefits in patients with early Alzheimer's disease.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.